Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 13/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 12/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.51 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.51 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3844101 | 1.00 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1HRH3SLC6A4MBTD1 | |
| SCHEMBL1735133 | 0.88 | L3MBTL3 (0.69) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL3839543 | 0.88 | L3MBTL3 (0.69) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL3862100 | 0.85 | L3MBTL1 (0.70) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL1735966 | 0.85 | L3MBTL1 (0.70) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL1735976 | 0.85 | L3MBTL1 (0.70) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL3846297 | 0.85 | L3MBTL1 (0.70) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL1736227 | 0.84 | L3MBTL1 (0.60) | L3MBTL3L3MBTL1HRH3SLC6A4MBTD1 | |
| SCHEMBL3846302 | 0.84 | L3MBTL1 (0.60) | L3MBTL3L3MBTL1HRH3SLC6A4MBTD1 | |
| SCHEMBL1736190 | 0.83 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1HRH3SLC6A4MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027086-B1 | N-BENZOYL-PYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH LLC (US) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131464-A1 | LOW IGNITION PROPENSITY SMOKING ARTICLE AND AN APPARATUS AND METHOD FOR FORMING A LOW IGNITION PROPENSITY SMOKING ARTICLE | BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED (GB) | 2011-10-27 | — | — | WO | claimed |
| US-7842715-B2 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-11-30 | — | — | US | claimed |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | claimed |
| US-7842715-B2 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2027086-A2 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007136668-A2 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | HRH4, HRH3, HRH2 | L3MBTL3 2436/4885L3MBTL1 3689/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.